>>Signaling Pathways>> Cancer Biology>>4-(4,4,5,5-Tetramethyl-1,3,2-dioxaboran-2yl)aniline

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaboran-2yl)aniline (Synonyms: 4-Aminophenylboronic Acid pinacol ester)

Catalog No.GC46606

A heterocyclic building block

Products are for research use only. Not for human use. We do not sell to patients.

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaboran-2yl)aniline Chemical Structure

Cas No.: 214360-73-3

Size 가격 재고 수량
1 g
US$83.00
재고 있음
5 g
US$272.00
재고 있음
10 g
US$11.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaboran-2yl)aniline is a heterocyclic building block.1,2 It has been used in the synthesis of 3-aminoindazole-based multi-targeted receptor tyrosine kinase (RTK) inhibitors with anticancer activity and roscovitine derivatives that are dual inhibitors of cyclin-dependent kinases (CDKs) and casein kinase 1 (CK1).

1.Dai, Y., Hartandi, K., Ji, Z., et al.Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitorJ. Med. Chem.50(7)1584-1597(2007) 2.Paraiso, K.H.T., Haarberg, H.E., Wood, E., et al.The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanismsClin. Cancer Res.18(9)2502-2514(2012)

리뷰

Review for 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaboran-2yl)aniline

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaboran-2yl)aniline

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.